<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213096</url>
  </required_header>
  <id_info>
    <org_study_id>Population Council #323</org_study_id>
    <secondary_id>HRN-A-00-99-00010</secondary_id>
    <nct_id>NCT00213096</nct_id>
  </id_info>
  <brief_title>Effects of Hormonal Contraceptives on Liver Proteins and Coagulation Factors: A Comparison of a Contraceptive Vaginal Ring and an Oral Contraceptive</brief_title>
  <official_title>A Randomized, Open-Label Study Comparing the Effect of a Contraceptive Vaginal Ring Delivering Daily Doses of 150 Micrograms Nestorone and 15 Micrograms Ethinyl Estradiol to an Oral Contraceptive Containing 150 Micrograms of Levonorgestrel and 30 Micrograms of Ethinyl Estradiol Per Tablet on Hepatic Factors Including Coagulation Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Council</source>
  <brief_summary>
    <textblock>
      The purpose of this 3-month (cycle) study was to evaluate the effects of hormonal&#xD;
      contraceptives containing a progestin and an estrogen on liver proteins and coagulation&#xD;
      factors that are sensitive to estrogen. In this study, a contraceptive vaginal ring&#xD;
      containing Nestorone® (a progestin with no androgenic properties) and ethinyl estradiol was&#xD;
      compared to an oral contraceptive containing levonorgestrel (an androgenic progestin) and&#xD;
      ethinyl estradiol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this 3-month (cycle) study was to evaluate the effects of hormonal&#xD;
      contraceptives containing a progestin and an estrogen on liver proteins and coagulation&#xD;
      factors that are sensitive to estrogen. In this study, a contraceptive vaginal ring&#xD;
      containing Nestorone® (a progestin with no androgenic properties) and ethinyl estradiol was&#xD;
      compared to an oral contraceptive containing levonorgestrel (an androgenic progestin) and&#xD;
      ethinyl estradiol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the differences between contraceptive vaginal ring and oral contraceptive treatment groups in change from baseline to end of treatment in serum angiotensinogen and sex-hormone binding globulin.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the differences between contraceptive vaginal ring &amp; oral contraceptive treatment groups in change from baseline to end of treatment in serum or plasma concentrations of 15 other hepatic proteins, coagulation factors &amp; coagulation markers.</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Contraception</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women, aged 18-34 years, who did not wish to become pregnant for 3 months (or&#xD;
             5 months if first discontinuing oral contraceptives&#xD;
&#xD;
          -  Intact uterus and at least 1 ovary&#xD;
&#xD;
          -  Have regular menstrual cycles (28 ± 7 days) or 2 regular cycles after parturition or&#xD;
             abortion&#xD;
&#xD;
          -  Willing to use condoms while having sexual intercourse during the 3 month study (or 5&#xD;
             months if discontinuing oral contraceptives), or&#xD;
&#xD;
          -  Willing to continue use of a specified non-hormonal method of birth control including&#xD;
             permanent sterilization, non-hormone-containing IUD, male condoms, or abstinence&#xD;
             during the study or to use condoms if discontinuing one of these methods&#xD;
&#xD;
          -  Willing and able to comply with the protocol&#xD;
&#xD;
          -  Willing and able to sign informed consent prior to entry into the study and prior to&#xD;
             discontinuing another method of contraception&#xD;
&#xD;
          -  Easy venous access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known hypersensitivity to estrogens or progestins&#xD;
&#xD;
          -  Known hypersensitivity to silicone rubber&#xD;
&#xD;
          -  Undiagnosed vaginal discharge or vaginal lesions or abnormalities&#xD;
&#xD;
          -  Smoking status: &gt;15 cigarettes per day&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Current or past thrombophlebitis or thromboembolic disorders&#xD;
&#xD;
          -  Family history of venous thrombosis or embolism (1st degree relatives &lt;55 years of&#xD;
             age)&#xD;
&#xD;
          -  Known history of Factor V Leiden or positive screening test for APC-resistance&#xD;
&#xD;
          -  Current or past cerebrovascular or coronary artery disease&#xD;
&#xD;
          -  Carcinoma (hormone-dependent tumor; past history of any carcinoma not in remission for&#xD;
             &gt;5 years)&#xD;
&#xD;
          -  Medically diagnosed severe depression&#xD;
&#xD;
          -  Headaches with focal neurological symptoms&#xD;
&#xD;
          -  Undiagnosed abnormal genital bleeding&#xD;
&#xD;
          -  History of cholestatic jaundice of pregnancy or jaundice with prior steroid use&#xD;
&#xD;
          -  Benign or malignant liver tumors; active liver disease&#xD;
&#xD;
          -  Diastolic/systolic BP ≥90/140 mmHg after 5 min. rest&#xD;
&#xD;
          -  Known or suspected alcoholism (&gt;2 drinks/day)or drug abuse&#xD;
&#xD;
          -  Positive for hepatitis B &amp; C and/or HIV 1 or 2, abnormal screening CBC, serum&#xD;
             chemistry values (including fasting, total cholesterol and triglycerides), abnormal&#xD;
             Pap smear, abnormal findings on dipstick urinalysis, or an abnormal electrocardiogram&#xD;
             (ECG)&#xD;
&#xD;
          -  Participation in a clinical trial within last 3 months or more than 1 trial in the&#xD;
             last year&#xD;
&#xD;
          -  BMI (kg/m2) &gt;28&#xD;
&#xD;
          -  Use of injectable contraceptives in last 6 months (e.g. cyclofem or DMPA)&#xD;
&#xD;
          -  Unwilling to stop oral contraceptives for 2 months prior to study initiation&#xD;
&#xD;
          -  Use of implanted hormonal contraceptives, including Mirena or Implanon, in last 2&#xD;
             years&#xD;
&#xD;
          -  Not living in the catchment area of the clinic*Severe cystoceles or rectoceles&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regine Sitruk-Ware, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <keyword>Contraceptive agents</keyword>
  <keyword>female</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>ST 1435</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

